Analytical Scale Isolation and Purification of Propranolol Impurities Including Nitrosamine Drug Substance Related Impurity (NDSRI)

Importance of the Topic

The presence of nitrosamine drug substance–related impurities (NDSRIs) in pharmaceuticals presents a significant safety concern due to their potential carcinogenicity. These impurities can arise during manufacturing or storage when APIs react with residual nitrosating agents, requiring reliable analytical workflows to isolate, characterize, and quantify them for regulatory compliance and patient safety.

Objectives and Overview of the Study

This application note describes an analytical-scale workflow for isolating and purifying N-nitroso-propranolol and other trace-level impurities of the propranolol API. The main goals were to develop a chromatography method with high resolution, implement mass-directed fraction collection, and verify the purity of isolated fractions using orthogonal techniques.

Methodology and Instrumentation

The purification strategy employed liquid chromatography with mass-triggered fraction collection followed by orthogonal verification. Key elements include:

• Chromatography system: Waters Arc Premier with binary or quaternary solvent managers and flow-through needle injectors
• Detectors: 2998 Photodiode Array (PDA) and ACQUITY QDa II Mass Detector
• Fraction collector: Waters Fraction Manager–Analytical (WFM-A)
• Columns: XSelect Premier CSH C18 and Premier HSS T3, both 4.6 × 100 mm, 2.5 µm
• Software: MassLynx with FractionLynx Application Manager and Empower CDS

Main Results and Discussion

The initial method achieved baseline separation of propranolol and N-nitroso-propranolol, with the latter detected at m/z 289 [M+H]+. Mass-triggered and time-based fraction collection enabled targeted isolation of the impurity. Purity assessment on an orthogonal HSS T3 column showed 96.1% chromatographic purity and confirmed spectral homogeneity. To resolve a co-eluting minor impurity, a shallow focused gradient was designed using a dedicated calculator. This approach enhanced resolution without extending run time, allowing successful collection of multiple low-level impurities.

Benefits and Practical Applications

The described workflow offers:

• Efficient isolation of trace-level nitrosamine impurities using mass-directed fraction collection
• Enhanced resolution and fast separations via sub-5 µm analytical columns and focused gradients
• High-purity reference materials for structural characterization and quantitation
• Adaptability to various APIs and impurity profiles in pharmaceutical quality control

Future Trends and Possibilities

Advances in fraction collection automation, real-time mass guidance, and gradient optimization tools will further streamline impurity isolation. Integration with high-throughput and AI-driven method development platforms can accelerate reference standard generation. Broader application to other nitrosamines and emerging impurity classes will support regulatory compliance and risk mitigation.

Conclusion

This study demonstrates a robust analytical-scale isolation and purification workflow for propranolol impurities, leveraging mass-triggered fraction collection and focused gradients. The approach yields high-purity fractions suitable for further structural characterization and reference standard use, offering a versatile solution for pharmaceutical impurity management.

References

1. Razvan C. Cioc, Ciarán Joyce, Monika Mayr, Robert N. Bream. Formation of N-Nitrosamine Drug Substance-Related Impurities in Medicines: A Regulatory Perspective on Risk Factors and Mitigation Strategies. Organic Process Research & Development. 2003;27(10).
2. Nakka S, Muchakayala SK, Surya SBM. Strategic Approaches to Elevate Quality and Sustainability of NDSRIs Method Development: Synthesis and Simultaneous Quantification Study of Multiple Tamsulosin NDSRIs. Microchemical Journal. 2025;214:114065.
3. Li X, Le Y, Seo JE, Guo X, Li Y, Chen S, et al. Revisiting the Mutagenicity and Genotoxicity of N-nitroso-Propranolol in Bacterial and Human in Vitro Assays. Regulatory Toxicology and Pharmacology. 2023;141:105410.
4. International Conference on Harmonization. ICH Q3A(R2): Impurities in New Drug Substances. 2006.
5. International Conference on Harmonization. ICH Q3B(R2): Impurities in New Drug Products. 2006.
6. U.S. Food and Drug Administration. Guidance for Industry Q3A Impurities in New Drug Substances. 2008.
7. Prajapati PB, Wankhed N, Mehta PJ. A Review on Multi Approaches for Impurity Isolation and its Characterization. Journal of Drug Delivery & Therapeutics. 2019;9(4-A):793-802.
8. Jablonski J, Wheat TE, Diehl DM. Developing Focused Gradients for Isolation and Purification. Waters Application Note. 2009.
9. Cleary R, Lefebvre P. The Impact of Focused Gradients on the Purification Process. Waters Application Note. 2007.
10. Waters Corporation. Waters Focused Gradient Calculator. Online resource. 2025.